Vitalijus Eismontas, Vaidotas Turskis, Alvydas Česas, Algirdas Šlepavičius
The aim of the study is to summarize our first experience in cytoreductive surgery(CRS) combined with intraoperative intraperitoneal chemotherapy (HIPEC) in Klaipeda University hospital. Patients and methods. A retrospective analysis of our first 10 patients who were treated with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in Klaipeda University hospital within the years 2011.11-2012.08. Seven patients had cytoreduction plus HIPEC for peritoneal carcinomatosis (PC) of recurrent ovarian cancer underwent and 3 patients had cytoreduction plus HIPEC for PC of colorectal cancer. Were was preoperative (age, peritoneal carcinomatosis index, chemotherapy cycles), intraoperative (duration of surgery, blood loss, etc.) data analysis performed. Results. 10 patients underwent cytoreduction plus HIPEC for PC of colorectal cancer and ovarian cancer in Klaipeda University hospital. The median of peritoneal carcinomatosis index (PCI) for patients with advanced ovarian cancer was 12,7 (6-22). Radical secondary cytoreductive surgery (CC-O/CC-1) was achieved in all patients. The median of PCI for patients with advanced colorectal cancer was 10,7 (8-12). Radical resection (CC-O) was achieved for all patients. A temporary postoperative agranulocytosis developed in one patient after surgery. We don‘t have early postoperative mortality.Disease progression was determined in 2 patients. Two patients died due to disease progression 12 and 14 months after surgery. CRS and HIPEC schould be performed in tertiary level centers with a multidisciplinary team . A good patients selection is very important to achieve good results.
Keyword(s): ovarian cancer, colorectal cancer, systemic che¬motherapy, cytoreduction, intraperitoneal chemotherapy
Full Text: PDF